维力医疗
(603309)
| 流通市值：40.25亿 | | | 总市值：40.25亿 |
| 流通股本：2.92亿 | | | 总股本：2.92亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 356,975,553.03 | 1,631,174,995.72 | 1,191,172,720.75 | 745,161,624.74 |
| 营业收入 | 356,975,553.03 | 1,631,174,995.72 | 1,191,172,720.75 | 745,161,624.74 |
| 二、营业总成本 | 288,079,414.9 | 1,358,927,688.58 | 966,698,297.98 | 599,681,370.35 |
| 营业成本 | 191,219,349.17 | 901,436,174.7 | 664,906,561.63 | 409,560,013.62 |
| 税金及附加 | 4,843,238.32 | 21,562,308.89 | 15,471,485.99 | 10,123,699.17 |
| 销售费用 | 29,189,138.92 | 167,953,487.06 | 104,430,660.99 | 62,629,712.38 |
| 管理费用 | 31,894,721.72 | 133,542,868.46 | 98,956,730.23 | 62,914,737.54 |
| 研发费用 | 22,211,855.54 | 115,659,050.88 | 71,257,900.33 | 46,634,095.32 |
| 财务费用 | 8,721,111.23 | 18,773,798.59 | 11,674,958.81 | 7,819,112.32 |
| 其中:利息费用 | 3,468,301.87 | 18,192,949.82 | 10,913,575.51 | 8,786,344.13 |
| 其中:利息收入 | 666,902.17 | 6,565,594.06 | 5,102,843.49 | 3,264,530.51 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 417,905.23 | 1,590,286.96 | 1,100,977.01 | 326,183.14 |
| 加:投资收益 | 673,785.92 | 1,681,463.96 | 1,546,296.66 | 1,569,236.69 |
| 资产处置收益 | 8,327.78 | 41,993.69 | -101,235.34 | -2,304.82 |
| 资产减值损失(新) | -305,795.73 | -156,568,581.65 | -2,448,544.02 | -2,313,359.83 |
| 信用减值损失(新) | 919,507.3 | -2,104,260.22 | -320,039.75 | -263,362.4 |
| 其他收益 | 2,505,787.87 | 13,582,782.22 | 10,782,739.31 | 4,779,121.67 |
| 四、营业利润 | 73,115,656.5 | 130,470,992.1 | 235,034,616.64 | 149,575,768.84 |
| 加:营业外收入 | 159,992.92 | 692,587.37 | 350,095.2 | 292,090.78 |
| 减:营业外支出 | 158,441.98 | 883,197.21 | 459,317.5 | 320,410.22 |
| 五、利润总额 | 73,117,207.44 | 130,280,382.26 | 234,925,394.34 | 149,547,449.4 |
| 减:所得税费用 | 11,225,827.18 | 43,155,264.49 | 35,130,219.65 | 22,517,024.83 |
| 六、净利润 | 61,891,380.26 | 87,125,117.77 | 199,795,174.69 | 127,030,424.57 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 61,891,380.26 | 87,125,117.77 | 199,795,174.69 | 127,030,424.57 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 59,945,543.63 | 76,327,701.25 | 191,642,595.23 | 121,076,601.73 |
| 少数股东损益 | 1,945,836.63 | 10,797,416.52 | 8,152,579.46 | 5,953,822.84 |
| 扣除非经常损益后的净利润 | 58,158,052.02 | 67,634,775.93 | 184,371,840.43 | 117,620,532.54 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.21 | 0.26 | 0.65 | 0.41 |
| (二)稀释每股收益 | 0.21 | 0.26 | 0.65 | 0.41 |
| 八、其他综合收益 | -957,104.01 | 4,577,794.73 | 4,481,304.95 | 3,607,059.26 |
| 归属于母公司股东的其他综合收益 | -909,248.82 | 4,348,904.99 | 4,257,239.7 | 3,426,706.3 |
| 九、综合收益总额 | 60,934,276.24 | 91,702,912.5 | 204,276,479.64 | 130,637,483.83 |
| 归属于母公司股东的综合收益总额 | 59,036,294.81 | 80,676,606.24 | 195,899,834.93 | 124,503,308.03 |
| 归属于少数股东的综合收益总额 | 1,897,981.43 | 11,026,306.26 | 8,376,644.71 | 6,134,175.8 |
| 公告日期 | 2026-04-23 | 2026-04-23 | 2025-10-21 | 2025-07-31 |
| 审计意见(境内) | | 标准无保留意见 | | |